Disclosure: D.B.S. is on the speakers panel for Athena Diagnostics and has received consultation fees from Accordant Health Services, Jacobus Pharmaceuticals, Bayhill Therapeutics, GSK, and Cytokinetics, Inc.
Cost analysis of myasthenia gravis from a large U.S. insurance database†
Version of Record online: 18 NOV 2011
Copyright © 2011 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 44, Issue 6, pages 907–911, December 2011
How to Cite
Guptill, J. T., Marano, A., Krueger, A. and Sanders, D. B. (2011), Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve, 44: 907–911. doi: 10.1002/mus.22212
- Issue online: 18 NOV 2011
- Version of Record online: 18 NOV 2011
- Accepted manuscript online: 23 JUN 2011 10:29AM EST
- Manuscript Accepted: 17 JUN 2011
- cost analysis;
- cost of illness;
- healthcare costs;
- myasthenia gravis
Little is known about the costs of managing rare diseases, and comprehensive healthcare costs have not been reported for myasthenia gravis (MG). We evaluated the direct costs and healthcare resource utilization in insured MG patients.
Costs were obtained from 1288 patients diagnosed with MG who were identified from the Accordant Health Services nationwide medical and pharmacy claims database.
Average annual medical/pharmacy claims costs per patient were: $6710/$1196 (age 0–19 years); $17,949/$19,573 (20–39 years); $15,112/$12,498 (40–64 years); and $12,597/$8,089 (65+ years). Total annual MG-related pharmacy costs were $9.4 million; IVIg accounted for 85% of all MG-related pharmacy costs. Non-steroidal immunosuppressives, cholinesterase inhibitors, and corticosteroids accounted for 9.3%, 5.7%, and 0.2% of pharmacy costs, respectively.
Costs related to the treatment of MG are higher than those of many other chronic neurological diseases. A large percentage of costs result from IVIg use, particularly among a subset of patients who receive frequent IVIg infusions. Muscle Nerve 2011